This biopharmaceutical company has seen two positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
KaloBios Pharmaceuticals currently holds a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Investors interested in the broader medical sector may consider other well-placed stocks like Myriad Genetics Inc. (MYGN), Gilead Sciences Inc. (GILD) and Illumina Inc. (ILMN). All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment